CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM074858
Első szerző:Aalto, Yan
Cím:Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion / Y. Aalto, W. El-Rifai, L. Vilpo, J. Ollila, B. Nagy, M. Vihinen, J. Vilpo, S. Knuutila
Dátum:2001
ISSN:0887-6924
Megjegyzések:Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with regard to its clinical course. The limitations of the methods currently available for prognostic assessment in CLL do not allow accurate prediction of the risk of disease progression in individual patients. The recently developed cDNA array technique provides a unique opportunity to study gene expression in various malignancies. To identify new molecular markers for prognostication of CLL patients, we analyzed cDNA arrays by using hierarchical clustering and standard statistic t-test on 34 CLL patients. We found significant expression differences in 78 genes compared to the reference tonsillar B lymphocytes. A cluster of genes, LCP1, PARP, BLR1, DEK, NPM, MCL1, SLP76, STAM, HIVEP1, EVI2B, CD25, HTLF, HIVEP2, BCL2, MNDA, PBX3, EB12, TCF1, CGRP, CD14, ILB, GZMK, GPR17 and CD79B, was associated (P < 0.05) with the unfavorable 11q deletion and also with the unfavorable Binet stages B and C. We present here gene expression profiling that is associated with CLL patients with the 11q23 deletion. Many of the genes in the cluster have not previously been shown to be related to the initiation or progression of CLL. These novel findings provide fundamental information for further attempts to understand the interaction of the clustered genes in the leukomogenesis of CLL in order to better design treatments aimed at specific molecular target(s).
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
gene expression
deletion 11q23
CLL
Megjelenés:Leukemia. - 15 : 11 (2001), p. 1721-1728. -
További szerzők:El-Rifai, Wa'el Vilpo, L. Ollila, Juha Nagy Bálint (1956-) (molekuláris genetikus) Vihinen, Mauno Vilpo, Juhani Knuutila, Sakari
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM075323
Első szerző:Casas, Silvia
Cím:Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia / Sílvia Casas, Bálint Nagy, Erkki Elonen, Anna Aventín, Marcelo L. Larramendy, Jorge Sierra, Tapani Ruutu, Sakari Knuutila
Dátum:2003
ISSN:1042-8194
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Leukemia & Lymphoma. - 44 : 11 (2003), p. 1935-1941. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Elonen, Erkki Aventín, Anna Larramendy, Marcelo L. Sierra, Jorge Ruutu, Tapani Knuutila, Sakari
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM065230
Első szerző:Galimberti, Sara
Cím:Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms / Sara Galimberti, Balint Nagy, Eugenio Ciancia, Francesco Caracciolo, Edoardo Benedetti, Matteo Pelosini, Daniele Focosi, Mario Petrini
Dátum:2010
ISSN:1042-8194
Megjegyzések:Notwithstanding the most recent and effectivetherapeutic strategies, in the majority of patientsmantle cell lymphoma (MCL) is still aggressive, withmedian overall survival (OS) ranging from 26 to 57months, when patients are stratified according to themantle cell lymphoma international prognostic index(MIPI) [1,2]. Thus, several immunochemotherapycombinations have been explored to improve outcome,such as R-Hyper-CVAD (rituximab plushyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, methotrexate, cytarabine)[2], R-CHOP (rituximab plus cyclophosphamide,doxorubicin, vincristine, prednisone) [3],maxi-CHOP [4], bortezomib plus R-CHOP [5],and mTOR (mammalian target of rapamycin)inhibitors [6]. Moreover, also autologous transplantstill remains a valid therapeutic option for youngpatients responsive to dose-intensified inductionchemotherapy, with 6-year overall survival andprogression-free survival of 70% and 66%, respectively[7].
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
mantle cell lymphoma
VEGF
Polymorphism
Megjelenés:Leukemia & Lymphoma 52 : 1 (2010), p. 142-144. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Ciancia, Eugenio Caracciolo, Francesco Benedetti, Edoardo Pelosini, Matteo Focosi, Daniele Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM065423
Első szerző:Galimberti, Sara
Cím:Evaluation of the MDR1, ABCG2, Topoisomerases IIα and GST[pi] gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen / Sara Galimberti, Balint Nagy, Edoardo Benedetti, Simone Pacini, Stefania Brizzi, Francesco Caracciolo, Federico Papineschi, Elena Ciabatti, Francesca Guerrini, Rita Fazzi, Martina Canestraro, Mario Petrini
Dátum:2009
ISSN:1042-8194
Megjegyzések:The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of otherindolent lymphoproliferative disorders, Topoisomerase IIa, glutathione-s-transferasep (GSTp) and ABCG2 (BCRP)chemoresistance genes being over-expressed in MCL. In our study, expression levels of the above mentioned genes plusMDR1 were tested on bone marrow samples from 20 patients treated with Rituximab plus hyper-CVAD regimen, in order toevaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen. All patients expressedABCG2 and MDR1 genes; 85% of cases expressed GSTp and topoisomerase IIa. Only ABCG2 were over-expressed incomparison both with marrow from healthy donors and tonsilar CD5?/CD20? lymphocytes (adopted as normal counterpart of the neoplastic population). The overall response rate of the entire series was 87.5%, with 44% of complete responses.Fifty-seven percent of patients achieved the clearance of minimal residual disease. Levels of tested genes did not condition either quality of clinical response or PFS (76% at 24 months). Nevertheless, an ABCG2 higher expression appeared associated with a worse PFS and levels of this gene paralleled the status of minimal residual disease. A further evaluation ofABCG2 expression in larger series of MCL patients would be suitable.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
MDR1
ABCG2
topoisomerases
mantle
cell
lymphoma
Megjelenés:Leukemia & Lymphoma. - 48 : 8 (2009), p. 1502-1509. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Benedetti, Edoardo Pacini, Simone Brizzi, Stefania Caracciolo, Francesco Papineschi, Federico Ciabatti, Elena Guerrini, Francesca Fazzi, Rita Canestraro, Martina Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM065302
Első szerző:Nagy Bálint (molekuláris genetikus)
Cím:RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma / Nagy Bálint, Galimberti Sara, Benedetti Edoardo, Caracciolo Francesco, Pacini Simone, Vilpo Juhani, Ferrer Anna, Elonen Erkki, Franssila Kaarle, Knuutila Sakari, Petrini Mario
Dátum:2007
ISSN:0145-2126
Megjegyzések:Our results show over-expression of RAF-1 in MCL versus tonsilar B-cell population. The absence of significance versus normal bone marrows could be related to variability of neoplastic infiltration and, perhaps, to the microenvironment, that in MCL would be particularly relevant [11].The observation of a clinical prognostic significance of RAF-1 would be useful in the stratification of cases on the basis of a "biological risk".This would be particularly relevant in the context of the R-Hyper-CVAD regimen that, notwithstanding its high clinical efficacy (even in the eradicating minimal residual disease) has a not negligible toxicity (in our series, 30% of infective complications, with two patients who died because of sepsis).Consequently, if the prognostic role of RAF-1 over-expression will be confirmed in larger series of patients, different therapeutic strategies would be adopted in the treatment of MCL.In this line, Sorafenib, an oral multi-kinase inhibitor that targets also RAF kinases would be an interesting compound [12] for treatment of mantle cell lymphoma.
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
RAF-1
overexpression
mantle cell lymphoma
Megjelenés:Leukemia Research. - 31 : 11 (2007), p. 1595-1597. -
További szerzők:Galimberti, Sara Benedetti, Edoardo Caracciolo, Francesco Pacini, Simone Vilpo, Juhani Ferrer, Anna Elonen, Erkki Franssila, Kaarle Knuutila, Sakari Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM065344
Első szerző:Niini, Tarja
Cím:Expression of myeloid-specific genes in childhood acute lymphoblastic leukemia : a cDNA array study / T. Niini, K. Vettenranta, J. Hollmén, M. L. Larramendy, Y. Aalto, H. Wikman, B. Nagy, J. K. Seppänen, A. Ferrer Salvador, H. Mannila, U. M. Saarinen-Pihkala, S. Knuutila
Dátum:2002
ISSN:0887-6924
Megjegyzések:Several specific cytogenetic changes are known to be associated with childhood acute lymphoblastic leukemia (ALL), and many of them are important prognostic factors for the disease. Little is known, however, about the changes in gene expression in ALL. Recently, the development of cDNA array technology has enabled the study of expression of hundreds to thousands of genes in a single experiment. We used the cDNA array method to study the gene expression profiles of 17 children with precursor-B ALL. Normal B cells from adenoids were used as reference material. We discuss the 25 genes that were most over-expressed compared to the reference. These included four genes that are normally expressed only in the myeloid lineages of the hematopoietic cells: RNASE2, GCSFR, PRTN3 and CLC. We also detected over-expression of S100A12, expressed in nerve cells but also in myeloid cells. In addition to the myeloid-specific genes, other over-expressed genes included AML1, LCP2 and FGF6. In conclusion, our study revealed novel information about gene expression in childhood ALL. The data obtained may contribute to further studies of the pathogenesis and prognosis of childhood ALL.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
expression
gene
myeloid
ALL
CDNA
array
Megjelenés:Leukemia. - 16 : 11 (2002), p. 2213-2221. -
További szerzők:Vettenranta, Kim Hollmén, Jaakko Larramendy, Marcelo L. Aalto, Yan Wikman, Harriet Nagy Bálint (1956-) (molekuláris genetikus) Seppänen, Jouni K. Salvador, Aurora Ferrer Mannila, Heikki Saarinen-Pihkala, Ulla Maija Knuutila, Sakari
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1